Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,668 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. Douglas RS, et al. Among authors: antonelli a. N Engl J Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434. N Engl J Med. 2020. PMID: 31971679 Clinical Trial.
Teprotumumab for Thyroid-Associated Ophthalmopathy.
Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS. Smith TJ, et al. Among authors: antonelli a. N Engl J Med. 2017 May 4;376(18):1748-1761. doi: 10.1056/NEJMoa1614949. N Engl J Med. 2017. PMID: 28467880 Free PMC article. Clinical Trial.
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, Dailey R, Harris GJ, Schiffman J, Tang R, Wester S, Jain AP, Marcocci C, Marinò M, Antonelli A, Eckstein A, Führer-Sakel D, Salvi M, Sile S, Francis-Sedlak M, Holt RJ, Smith TJ. Douglas RS, et al. Among authors: antonelli a. Ophthalmology. 2022 Apr;129(4):438-449. doi: 10.1016/j.ophtha.2021.10.017. Epub 2021 Oct 21. Ophthalmology. 2022. PMID: 34688699 Free article. Clinical Trial.
Sorafenib in the treatment of thyroid cancer.
Ferrari SM, Politti U, Spisni R, Materazzi G, Baldini E, Ulisse S, Miccoli P, Antonelli A, Fallahi P. Ferrari SM, et al. Among authors: antonelli a. Expert Rev Anticancer Ther. 2015;15(8):863-74. doi: 10.1586/14737140.2015.1064770. Epub 2015 Jul 7. Expert Rev Anticancer Ther. 2015. PMID: 26152651
Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
Fallahi P, Ferrari SM, Elia G, Ragusa F, Paparo SR, Patrizio A, Camastra S, Miccoli M, Cavallini G, Benvenga S, Antonelli A. Fallahi P, et al. Among authors: antonelli a. Front Endocrinol (Lausanne). 2021 Apr 16;12:654473. doi: 10.3389/fendo.2021.654473. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33935970 Free PMC article. Review.
Teprotumumab for the treatment of thyroid eye disease.
Fallahi P, Ragusa F, Paparo SR, Elia G, Balestri E, Mazzi V, Patrizio A, Botrini C, Benvenga S, Ferrari SM, Antonelli A. Fallahi P, et al. Among authors: antonelli a. Expert Opin Biol Ther. 2023 Feb;23(2):123-131. doi: 10.1080/14712598.2023.2172328. Epub 2023 Jan 29. Expert Opin Biol Ther. 2023. PMID: 36695097
New trends in the treatment of undifferentiated carcinomas of the thyroid.
Miccoli P, Materazzi G, Antonelli A, Panicucci E, Frustaci G, Berti P. Miccoli P, et al. Among authors: antonelli a. Langenbecks Arch Surg. 2007 Jul;392(4):397-404. doi: 10.1007/s00423-006-0115-8. Epub 2006 Nov 28. Langenbecks Arch Surg. 2007. PMID: 17131154 Review.
Sorafenib and thyroid cancer.
Fallahi P, Ferrari SM, Santini F, Corrado A, Materazzi G, Ulisse S, Miccoli P, Antonelli A. Fallahi P, et al. Among authors: antonelli a. BioDrugs. 2013 Dec;27(6):615-28. doi: 10.1007/s40259-013-0049-y. BioDrugs. 2013. PMID: 23818056 Review.
1,668 results